Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:XYZ_Pharma
|
| gptkbp:awards |
Innovation Award 2021
Best_Pharma_Company_2020 |
| gptkbp:CEO |
Jane_Smith
|
| gptkbp:clinicalTrials |
Phase 2 Trials
Collaboration with Universities Phase 3 Trials Phase 1 Trials Partnership_with_Research_Institutes |
| gptkbp:communityInvolvement |
Charity Donations
Health Awareness Programs Volunteer_Programs |
| gptkbp:customerBase |
Hospitals
Pharmacies Healthcare_Providers |
| gptkbp:employees |
500
|
| gptkbp:financialPerformance |
Consistent Growth
Positive Cash Flow Strong Profit Margins |
| gptkbp:founded |
1993
|
| gptkbp:founder |
gptkb:Dr._John_Doe
|
| gptkbp:futurePlans |
Increase Global Reach
Enhance R&D Capabilities Expand_Product_Line |
| gptkbp:globalPresence |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:headquarters |
gptkb:New_York,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
IDEX Pharmaceutical
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:investmentFocus |
$50 million in R&D
$10 million in technology $20 million in infrastructure |
| gptkbp:market |
$1 billion
|
| gptkbp:partnerships |
gptkb:ABC_Corp.
|
| gptkbp:patentCitation |
50+ patents
|
| gptkbp:products |
Generic_Drugs
Specialty_Pharmaceuticals |
| gptkbp:regulatoryCompliance |
EMA_Approved
FDA_Approved |
| gptkbp:researchFocus |
Cardiology
Oncology Neurology |
| gptkbp:revenue |
$200 million
|
| gptkbp:services |
Contract Manufacturing
Research_and_Development |
| gptkbp:stockSymbol |
gptkb:IDEX
|
| gptkbp:subsidiary |
gptkb:IDEX_Biotech
|
| gptkbp:sustainabilityInitiatives |
Green Manufacturing
Energy Efficiency Projects Waste Reduction Programs |
| gptkbp:training |
Leadership Development Programs
Safety Training Programs Continuous_Education_Programs |
| gptkbp:website |
www.idexpharmaceutical.com
|